Bladder Cancer

Collectively, our findings establish the H3K18la-HNRNPF-Parkin axis as a previously unrecognized signaling cascade that bridges epigenetic reprogramming and mitochondrial quality control in chemoresistance. Targeting this axis, particularly the HNRNPF-Parkin interaction or mitophagy activation, presents a novel therapeutic strategy to overcome cisplatin resistance in BCa.

Early recognition and management are crucial for improving patient prognosis. A thorough understanding of the pathogenesis of ICI-IA is essential for optimizing treatment strategies and improving quality of life.

P3, N=190, Not yet recruiting, Brigham and Women's Hospital

After a complete characterization of Ca Ski sEVs (NTA, microscopy, PCR, western-blotting), our data show for the first time, a functional transfer of HPV16 early transcripts via EVs driving the proliferation of HPV-negative target cells. EV-loaded HPV16 e6/e7 mRNA could be used as early biomarkers before the disease sets in and to predict the evolution of cervical precancerous lesions towards cancer and facilitate patient monitoring through a simple liquid biopsy.

FLNC drives BC progression and metastasis via MAPK/ERK activation and EMT induction.

P1/2, N=54, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2026 --> Nov 2027

P2, N=58, Recruiting, Peking University Third Hospital

PI3K/AKT/mTOR pathway activity was examined by Western blot, and its function validated using SC79 (AKT activator) and LY294002 (PI3K inhibitor)...By modulating the PI3K/AKT/mTOR signaling axis and the pro-angiogenic microenvironment, ADGRD1 facilitates tumor growth and neovascularization. ADGRD1 may serve as a promising prognostic biomarker and therapeutic target for advanced BLCA.

P=N/A, N=200, Recruiting, Memorial Sloan Kettering Cancer Center

P=N/A, N=500, Recruiting, Centre Hospitalier Universitaire, Amiens | Trial completion date: Jan 2024 --> Dec 2028 | Trial primary completion date: Jan 2024 --> Dec 2028

Critically, most mechanistic findings remain at the preclinical or retrospective validation stage, with no markers yet approved for routine clinical use. Future work must prioritize longitudinal paired clinical samples, standardized analytic assays for dynamic biomarkers, and the integration of functional models (organoids, microfluidic systems), multi-omics technologies (single-cell sequencing, spatial transcriptomics), and liquid-biopsy approaches to translate mechanistic discoveries into clinically actionable predictive tools and therapeutic strategies.

Combined treatment with the MEK inhibitor TAK-733 and immune checkpoint inhibitors was proposed as a promising therapeutic strategy for this subgroup. This novel VM-based molecular subtyping system for MIBC shows strong potential for clinical application in prognosis prediction, immunotherapy response evaluation, and targeted drug discovery, providing a framework to guide personalized treatment strategies for MIBC patients.